Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Breast cancer, female
Trial Type:  Prevention
Trial Status:  Active
Sponsor of Trial:  NCI
Results 1-5 of 5 for your search:
Start Over
Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Status: Approved-not yet active
Age: 25 to 55
Sponsor: NCI, Other
Protocol IDs: A211102, U10CA031946, NCI-2013-00995, NCT01905046
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 25 and over
Sponsor: NCI, Other
Protocol IDs: 08218, R01CA140245-01, NCI-2010-01976, NCT01196936
Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00859, 12-474, 12-267, N01-CN-2012-00034, AAAK6752, MSKCC-12-267, H-33017, 2011-0766, MDA10-16-01, N01CN00034, N01CN35159, P30CA016672, NCT01849250
Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk
Phase: Phase II
Type: Prevention
Status: Active
Age: 30 to 45
Sponsor: NCI, Other
Protocol IDs: 1300000596, 1R01CA172444-01A1, NCT02028221
Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: IUCRO-0365, NCI-2013-00422, NCT01793948
Start Over